SEC Company Response from ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514) (ADMA) — May 23, 2012
ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)
Date: May 23, 2012 · CIK: 0001368514 · Accession: 0001193805-12-000967
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-52120
Referenced dates: May 9, 2012
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance ADMA Biologics, Inc. Amendment No. 2 to Form 8-K Filed April 24, 2012 File No. 000-52120
Dear Mr. Dobbie:
By letter dated May 9, 2012, you provided comments on the above-referenced filing of ADMA Biologics, Inc. (the “Company”). The Company currently expects to submit its response letter via EDGAR, along with an amendment to the above-referenced filing, on or before June 4, 2012.
If you have any questions, or if we may be of any assistance, please do not hesitate to contact the undersigned at (201) 478-5552 or Jeffrey Baumel or Roland Chase at our outside counsel, SNR Denton US LLP, at (973) 912-7100.
Sincerely,
/s/ Adam S. Grossman
Show Raw Text
CORRESP
1
filename1.htm
Unassociated Document
[ADMA LETTERHEAD]
May 23, 2012
VIA EDGAR
Mr. Justin Dobbie
Legal Branch Chief
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re:
ADMA Biologics, Inc.
Amendment No. 2 to Form 8-K
Filed April 24, 2012
File No. 000-52120
Dear Mr. Dobbie:
By letter dated May 9, 2012, you provided comments on the above-referenced filing of ADMA Biologics, Inc. (the “Company”). The Company currently expects to submit its response letter via EDGAR, along with an amendment to the above-referenced filing, on or before June 4, 2012.
If you have any questions, or if we may be of any assistance, please do not hesitate to contact the undersigned at (201) 478-5552 or Jeffrey Baumel or Roland Chase at our outside counsel, SNR Denton US LLP, at (973) 912-7100.
Sincerely,
/s/ Adam S. Grossman
Adam S. Grossman
President and Chief Executive Officer